Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Raiffeisen Bank International AG

Raiffeisen Bank International AG boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 30.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 11,609 shares of the biopharmaceutical company’s stock after buying an additional 2,705 shares during the quarter. Raiffeisen Bank International AG’s holdings in Alnylam Pharmaceuticals were worth $5,195,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Root Financial Partners LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth $25,000. Salomon & Ludwin LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at $27,000. Atlantic Union Bankshares Corp purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at $30,000. ORG Partners LLC boosted its position in shares of Alnylam Pharmaceuticals by 70.2% in the 3rd quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 33 shares during the period. Finally, Elevation Point Wealth Partners LLC purchased a new position in Alnylam Pharmaceuticals in the 2nd quarter worth about $37,000. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $336.19 on Friday. The company has a market capitalization of $44.59 billion, a PE ratio of 196.60 and a beta of 0.35. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. The company’s 50 day moving average price is $366.89 and its 200 day moving average price is $422.47. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.61). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same period last year, the business earned ($0.65) EPS. The company’s quarterly revenue was up 84.9% on a year-over-year basis. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on ALNY. Leerink Partners reduced their price objective on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research note on Monday, December 15th. Chardan Capital cut their price target on shares of Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Oppenheimer began coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price target for the company. Truist Financial lowered their price objective on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a research report on Thursday, January 8th. Finally, Bank of America reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $477.96.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 2,041 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $331.96, for a total value of $677,530.36. Following the transaction, the executive vice president owned 21,264 shares in the company, valued at $7,058,797.44. The trade was a 8.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Tolga Tanguler sold 1,959 shares of the company’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $607,446.72. Following the completion of the transaction, the executive vice president directly owned 31,769 shares in the company, valued at approximately $9,850,931.52. The trade was a 5.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 36,578 shares of company stock valued at $12,416,105. 1.50% of the stock is currently owned by company insiders.

Key Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Company reported ~ $3.0B in 2025 revenue (≈81% YoY) with Q4 net product revenue of $995M and a 151% surge in the TTR franchise — evidence of accelerating commercial momentum that supports longer‑term growth expectations. Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge
• Positive Sentiment: Canaccord Genuity raised its price target to $429, signaling stronger upside in analysts’ models and providing support for the stock’s valuation case. Canaccord Genuity Group Increases Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $429.00
• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating, and Freedom Capital upgraded ALNY to “Strong Buy” (reported via Zacks), adding buy‑side endorsement that could attract momentum investors. HC Wainwright Reaffirms “Buy” Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) Freedom Capital Upgrade via Zacks
• Neutral Sentiment: Some analysts trimmed targets after the latest reports while still expressing confidence in 2026 growth — a mixed read that leaves upside intact but tempers near‑term estimates. Analysts Trim Alnylam Pharmaceuticals, Inc. (ALNY) Targets but Keep Faith in 2026 Growth
• Neutral Sentiment: Independent valuation pieces highlight a divergence between recent share‑price performance and bullish fair‑value models — useful context for investors debating entry points. Assessing Alnylam Pharmaceuticals (ALNY) Valuation As Mixed Share Price Returns Meet Bullish Fair Value Models
• Negative Sentiment: Insider selling picked up this week: an EVP sold ~$607,447 of stock, and two other officers (Kevin Joseph Fitzgerald and Pushkal Garg) sold shares (2,041 and 2,242 shares respectively). Insider sales can create short‑term sentiment pressure even if they are routine. Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $607,446.72 in Stock Kevin Joseph Fitzgerald Sells 2,041 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Pushkal Garg Sells 2,242 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.